| 纯度 | >90%SDS-PAGE. |
| 种属 | Mouse |
| 靶点 | Scd1 |
| Uniprot No | P13516 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | MPAHMLQEISSSYTTTTTITAPPSGNEREKVKTVPLHLEEDIRPEMKEDIHDPTYQDEEGPPPKLEYVWRNIILMVLLHLGGLYGIILVPSCKLYTCLFGIFYYMTSALGITAGAHRLWSHRTYKARLPLRIFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGGKLDMSDLKAEKLVMFQRRYYKPGLLLMCFILPTLVPWYCWGETFVNSLFVSTFLRYTLVLNATWLVNSAAHLYGYRPYDKNIQSRENILVSLGAVGEGFHNYHHTFPFDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSKATVLARIKRTGDGSHKSS |
| 预测分子量 | 43.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SCD1重组蛋白的3篇文献示例(内容为模拟，非真实文献)：
1. **文献名称**：*Expression and Purification of Recombinant Mouse SCD1 in E. coli*
**作者**：Zhang Y, et al.
**摘要**：报道了通过大肠杆菌表达系统高效表达小鼠SCD1重组蛋白，并优化纯化步骤，获得高活性酶用于体外脂肪酸去饱和功能分析。
2. **文献名称**：*Structural Insights into Human SCD1 by Recombinant Protein Crystallography*
**作者**：Lee S, et al.
**摘要**：利用昆虫细胞系统表达人源SCD1重组蛋白，解析其晶体结构，揭示了底物结合域的关键氨基酸残基及催化机制。
3. **文献名称**：*Functional Characterization of Recombinant SCD1 in Lipid Metabolism Regulation*
**作者**：Cohen P, et al.
**摘要**：通过哺乳动物细胞表达重组SCD1.证明其过表达可显著增加单不饱和脂肪酸水平，并验证其在肝脏脂质代谢中的调控作用。
注：以上文献信息为虚构示例，实际文献需通过PubMed、Web of Science等数据库检索关键词“SCD1 recombinant protein”或“stearoyl-CoA desaturase 1 expression”获取。
**Background of Recombinant SCD1 Protein**
Stearoyl-CoA desaturase-1 (SCD1) is a key enzyme in lipid metabolism, catalyzing the conversion of saturated fatty acids (SFAs) like stearic acid (C18:0) and palmitic acid (C16:0) into monounsaturated fatty acids (MUFAs) by introducing a double bond in the Δ9 position. This reaction is critical for maintaining membrane fluidity, regulating metabolic homeostasis, and synthesizing triglycerides, phospholipids, and cholesterol esters. SCD1 is highly expressed in lipogenic tissues such as the liver, adipose, and skin, and its activity is tightly linked to insulin sensitivity, obesity, and inflammation. Dysregulation of SCD1 has been implicated in metabolic disorders, cardiovascular diseases, and cancer, making it a potential therapeutic target.
Recombinant SCD1 protein is produced using biotechnological methods, often through heterologous expression in bacterial (e.g., *E. coli*) or mammalian cell systems. These systems enable large-scale production of purified, active SCD1 for *in vitro* studies. Researchers utilize recombinant SCD1 to investigate its enzymatic kinetics, structural properties, and interactions with inhibitors or activators. For example, studies have focused on developing SCD1 inhibitors to modulate MUFA levels in metabolic diseases. Additionally, recombinant SCD1 is employed in cell-free assays to screen drug candidates or study post-translational modifications affecting its activity.
The availability of recombinant SCD1 has advanced understanding of its role in lipid-related pathologies and facilitated drug discovery. However, challenges remain, such as maintaining enzyme stability and mimicking its membrane-bound nature *in vitro*. Ongoing research aims to refine production techniques and explore SCD1's tissue-specific functions, offering insights into personalized therapies for metabolic syndromes and cancer.
×
